We recommend a postoperative hemoglobin threshold for transfusion in stable cyanotic cardiac children with clinical signs suggestive of symptomatic anemia as of 90 g/L. (2C)

There is no well- defined threshold for blood transfusion in advanced ovarian cancer surgery. Since many patients need chemotherapy, more liberal transfusion thresholds may be used. (II, B)

Tranexamic acid should be considered peri- operatively reduce blood loss. (I, B)

The use of intravenous albumin should not be considered as a substitute for nutritional support. (III, B)

Hypoalbuminemia should not be used as a single marker for patient selection for surgery but as guidance for pre- operative optimization of patients. (III, B)

Balanced crystalloids should be used for routine fluid replacement. (III, B)

Normothermia and the prevention of acidosis are critical to control bleeding effectively. A pH of 7.35–7.45 and a core body temperature of >34°C should be maintained. (III, A)

Replacement of combined blood and plasma products as well as pharmacologic agents to support coagulation pathways such as tranexamic acid are recommended in the management of intra- abdominal blood loss in well- defined algorithms. (III, A)

In patients at high risk for cardiovascular events due, for example, to previous ischemic heart disease, stents, or cerebrovascular disease, who are receiving antiplatelet monotherapy with aspirin and require ovarian cancer surgery, aspirin should be continued peri-operatively and intra-operatively. (II, B)

In patients at low risk for cardiovascular events who are receiving antiplatelet monotherapy with aspirin, it should be stopped 7 to 10 days before ovarian cancer surgery. (III, B)